jmdutton.com
Avigen, Inc.
Market Information
Symbol: AVGN
Exchange: NasdaqNM
Industry: Healthcare, Biotechnology & Pharmaceutical
Analyst
William R. Prather, RPh, MD
Dutton Associates Rating
Speculative Buy
Rating Information
Recent Price: $5.37 (9/18/2006)
Price Target: $8.00
Established: 6/12/2006
Price at Rating: $5.89
Time Frame: 12 Months
Other Information
Dutton Associates' Research on Avigen, Inc. (PDF format)
9/19/2006 Update Report Avigen Speculative Buy Rating In Update Coverage; On Track To Successfully And, In A Timely Manner, Meet Milestones Outlined In Our Initial Report Speculative Buy
6/12/2006 Initial Report Avigen Speculative Buy Rating In Initiating Coverage; Its Advantage Over Other Early BioPharmaceutical Companies: Their Primary Product Portfolio has Already Been Extensively Used Internationally Speculative Buy
Current Dutton Associates disclaimer and 17b disclosure information regarding Avigen, Inc.
Information, opinions or recommendations contained in Dutton Associates' research reports or research notes are submitted solely for advisory and information purposes. The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Such information and the opinions expressed are subject to change without notice. A Dutton Associates research report or note is not intended as an offering or a solicitation of an offer to buy or sell the securities mentioned or discussed. Neither the Firm, its principals, nor the assigned analysts own or trade shares of any company covered. The Firm does not accept any equity compensation. Anyone may enroll a company for research coverage, which currently costs US $39,500 prepaid for 4 Research Reports, typically published quarterly, and requisite Research Notes. Dutton Associates received $35,000 from the Company for 4 Research Reports with coverage commencing on 06/12/2006. Reports are performed on behalf of the public, and are not a service to any company. The analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests and insure independence. Please read full disclosure and other reports and notes on the Company at www.DuttonAssociates.com.
The views expressed in this research report or note accurately reflect the analyst's personal views about the subject securities or issuer. Neither the analyst's compensation nor the compensation received by Dutton Associates is in any way related to the specific recommendations or views contained in this research report or note.
Dutton Associates. John M. Dutton, President, 4989 Golden Foothill Parkway, Suite 4, El Dorado Hills, CA 95762 Phone (916) 941-8119, Fax (916) 941-8093
Periodic Research Reports and Research Notes on this Company are available at our web site: www.DuttonAssociates.com.
© Copyright 2006, by Dutton Associates |
